AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.2640
+0.0104 (4.10%)
At close: Aug 3, 2026, 4:00 PM EDT
0.2623
-0.0017 (-0.64%)
Pre-market: Aug 4, 2026, 5:34 AM EDT

AIM ImmunoTech Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.070.090.170.20.140.14
Revenue Growth
-27.72%-48.23%-15.84%43.26%4.44%-17.18%
Gross Profit
-0.05-0.040.140.160.14-0.72
Operating Income
-10.27-11.66-19.77-31.92-19.92-18.84
Net Income
-13.28-13.96-17.32-28.96-19.45-19.13
Earnings Per Share
-6.38-8.62-30.92-59.94-39.96-39.96
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5.883.053.9813.0734.1948.27
Total Debt
4.574.92.940.720.840.15
Net Cash (Debt)
1.31-1.851.0412.3533.3548.12
Net Cash Growth
---91.61%-62.97%-30.69%31.05%
Net Cash Per Share
0.52-1.141.8525.4069.35101.54

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-11.32-10.96-14.89-21.27-16.11-13.97
Capital Expenditures
---0.02--0.09-0.04
Free Cash Flow
-11.32-10.96-14.91-21.27-16.19-14.01
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-67.12%-45.45%81.76%79.21%100.00%-529.63%
Operating Margin
-14069.90%-13254.50%-11630.60%-15800.00%-14129.80%-13954.10%
Pretax Margin
-16000.00%-15861.36%-10188.24%-14337.62%-13790.78%-14168.15%
Profit Margin
-16000.00%-15861.40%-10188.20%-14337.60%-13790.80%-14168.10%
FCF Margin
-15500.00%-12451.10%-8768.24%-10528.20%-11485.10%-10374.80%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
62.0239.3877.01106.85105.72327.07